Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators plan to administer acetaminophen (Tylenol) for the treatment of fever in laboring patients by either an oral or intravenous (IV) route. The investigators want to see if the maternal fever will decrease faster with the IV or the oral dose. The investigators also want to look at other outcomes such as the cesarean section rate, the rate of neonatal intensive care unit admissions in both groups.
This is a randomized, controlled, study of intravenous (IV) acetaminophen (OFIRMEV) versus orally administrated acetaminophen for the reduction of intrapartum maternal fever and fetal tachycardia. Compared to oral acetaminophen, intravenous acetaminophen has increased bioavailability and more rapid onset of action. IV acetaminophen has been used successfully in the management of fever in post-operative patients. Additionally, intravenous acetaminophen has also been used in the intrapartum setting for management of pain.However, the use of intravenous acetaminophen for the treatment of maternal temperature and subsequent fetal tachycardia, has not yet been evaluated.
The study will have two arms that will be randomized in a 1:1 ratio. A double dummy, double blind, comparator controlled study design will be utilized. After inclusion criteria have been satisfied, subjects in the control arm will receive an oral dose 1000 mg acetaminophen and an intravenous placebo resembling Ofirmev. The subjects in the experimental arm will receive 1000 mg of IV Ofirmev and an oral placebo resembling acetaminophen. Both groups will receive standard obstetrical care, continuous fetal monitoring, and antibiotics if there is suspected chorioamnionitis. The blinding technique will eliminate provider bias.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intravenous Acetaminophen | Experimental | Subjects will receive 1000 mg of intravenous Acetaminophen q 6 hours, up to two doses and an oral placebo resembling oral acetaminophen |
|
| Oral Acetaminophen | Active Comparator | Subjects will receive 1000 mg of oral Acetaminophen q 6 hours, up to two doses and an intravenous placebo resembling intravenous acetaminophen |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intravenous Acetaminophen | Drug | 1000 mg Acetaminophen q 6 hours, given intravenously |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in Maternal Body Temperature | 01, 15, 30, 60 and 90, 120, 180, 240, 300, 360 minutes following Time 01 (Time 01 = time when first dose of acetaminophen was administered |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Fetal Heart Rate | 01, 15, 30, 60 and 90, 120, 180, 240, 300, 360 minutes following Time 01 (Time 01 = time when first dose of acetaminophen was administered | |
| Mode of Delivery (cesarean section vs vaginal delivery) | Measured at point of delivery |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nisha Lakhi, MD | Richmond University Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Richmond University Medical Center | Staten Island | New York | 10310 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33451627 | Derived | Mehraban S, Nematian S, Mehraban SS, Petrucci S, Tricorico G, Parnas Z, Shats L, Kanninen T, Moretti M, Cabbad M, Lakhi N. Randomized control trial of intravenous acetaminophen for reduction of intrapartum maternal fever. Am J Obstet Gynecol MFM. 2021 Jan;3(1):100287. doi: 10.1016/j.ajogmf.2020.100287. Epub 2020 Dec 9. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D005334 | Fever |
| ID | Term |
|---|---|
| D001832 | Body Temperature Changes |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000082 | Acetaminophen |
| ID | Term |
|---|---|
| D000083 | Acetanilides |
| D000813 | Anilides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D000814 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Oral Acetaminophen | Drug | 1000 mg Acetaminophen q 6 hours given orally |
|
|
| Number of Cesarean Deliveries for Persistent Fetal Tachycardia | Measured at the point of delivery |
| Number of Patients with Diagnosis of Clinical Chorioamnionitis | Measured from admission to 7 days post-partum |
| Number of Patients with Diagnosis of Histological Chorioamnionitis | Measured from placenta histology collected at delivery |
| Neonatal Apgar Score | One and Five minutes of life |
| Number of Infants Admitted to Neonatal Intensive Care Unit | First 7 days of life |
| Number of Infants with Culture Positive Neonatal Sepsis | First 7 days of life |
| Number of infants requiring additional respiratory intervention | First 24 hours of life |
| Number of Infants Developing Neonatal Seizures | First 7 days of life |
| Number of infants with fetal acidosis | Point of Delivery |
| Maternal Levels of Pro-Inflammatory Mediators | C-Reactive Protein (CRP), Tumor Necrosis Factor Alpha (TNF-α), Interleukin 6 (IL-6) | Admission and 4 hours after delivery |
| Levels of Pro-Inflammatory Mediator in Infant, collected from umbilical cord blood | C-Reactive Protein (CRP), Tumor Necrosis Factor Alpha (TNF-α), Interleukin 6 (IL-6) | Point of Delivery |
| Maternal Levels of Oxidative Stress Markers | Thioredoxin Reductase (TrxR), Gluathione (GSH) | Admission and 4 hours after delivery |
| Levels of Oxidative Stress Markers in Infant, collected from umbilical cord blood | Thioredoxin Reductase (TrxR), Gluathione (GSH) | point of delivery |
| Levels of Acetaminophen in Cord Blood | point of delivery |
| Maternal Liver Function Test | aspartate aminotransferase (AST), alanine aminotransferase (ALT) | 12-24 hours after delivery |
| Maternal White Blood Count (WBC) | Admission and 12-24 hours after delivery |
| Aniline Compounds |
| D000588 | Amines |